Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
Gabrail Cancer Center Research, Canton, Ohio, United States
Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Lahey Clinic, Burlington, Massachusetts, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Virginia Mason Hospital & Medical Center, Seattle, Washington, United States
University of California, San Francisco, San Francisco, California, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Cook Children's Medical Center, Fort Worth, Texas, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
Mount Sinai Medical Center, New York, New York, United States
Mayo Clinic (AZ), Scottsdale, Arizona, United States
Wayne State University Karmanos Cancer Institute, Detroit, Michigan, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Stony Brook University Cancer Center, Stony Brook, New York, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
University of Ulm, Ulm, Baden-Württemberg, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.